Bourgeon Capital Management’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Bourgeon Capital Management’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,000	Closed	-$42.2K	–	406
2023 Q4	$42.2K	Hold	7,000	–	–	0.01%	155
2023 Q3	$38.9K	Buy	+7,000	New	+$45.1K	0.01%	155
2023 Q2	–	Sell	-49,855	Closed	-$200K	–	360
2023 Q1	$200K	Buy	49,855 +46,355	+1,324%	+$226K	0.05%	92
2022 Q4	$11.4K	Buy	+3,500	New	+$14K	﹤0.01%	231

Other funds holding LBPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Bourgeon Capital Management's LBPH Position: Q1 2024 in Review

Bourgeon Capital Management sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q1 2024, closing a stake of 7,000 shares — an estimated $42.2K sold.

Bourgeon Capital Management first reported a position in LBPH in Q4 2022 and held it in 4 quarters. The position peaked at $200K in Q1 2023. 105 funds tracked by Wall St. Rank hold LBPH as of Q1 2024.

Bourgeon Capital Management reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Bourgeon Capital Management sold 7,000 Longboard Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $42.2K.
Bourgeon Capital Management first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
Bourgeon Capital Management's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $200K in Q1 2023.
105 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Bourgeon Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.